This is a list of recommendations on what to do with immunosuppressant drugs and COVID vaccine American College of Rheumatology Clinical Guidance Summary UPDATED JUN 2021 The above come from the FEB 2021 ACR published guidelines. You can find the entire article here Revised with new drugs to stop for vaccines 6/13/21 Bottom Line: You only need to adjust mycophenolate, methotrexate, Xeljanz, Olumiant, Rinvoq, Orencia, cyclophosphamide, rituximab, NSAIDs, and Tylenol Please check with your doctor and ask before implementing these. Your medical condition may dictate otherwise Resource: American College of Rheumatology ACR COVID-19 Vaccine Clinical Guidance Task Force (2/8/21). COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases. Retrieved on 2/25/21 from https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf AuthorDon Thomas, MD, author of "The Lupus Encyclopedia" and "The Lupus Secrets"
1 Comment
 Systemic Lupus Erythematosus (SLE) can go into remission on medications or treatment AuthorDon Thomas, MD author of "The Lupus Encyclopedia" and "The Lupus Secrets" Do not automatically stop hydroxychloroquine if your eye doctor tells you your patient has HCQ-retinopathy!  Normal SD-OCT from a 24 year old man credit: By Wies6014 - Own work, CC BY-SA 4.0, httpscommons.wikimedia.orgwindex.phpcurid=77634880 SD-OCT and VF 10-2 results have false positives. Don't stop your lupus patient's most important medicine without doing the following:Recommendations: - If your ophthalmologist advises you to stop HCQ based upon either an SD-OCT or VF 10-2 result, refer that patient to a good retinologist who has a mf-ERG machine - It is a good idea to have your staff call retinologists around your area and find out if they have this capability or not Rationale is below: (note that this statement is made with help from retinologists Dr. Jonathan Lyons and Dr. Reshma Katira in Silver Spring, MD and Alexandria, VA respectively. They specialize in HCQ-retinopathy. This section will appear in the 2nd edition of "The Lupus Encyclopedia," but it is important to make it known widely to help our patients) Mistakes in the medical literature We rheumatologists, and eye doctors who do not specialize in antimalarial retinopathy (AMR) need to be careful about the subtleties of making this diagnosis and the potential flaws of the screening tests. The 2014 Browning Clinical Ophthalmology article (so often cited for its sensitivities and specificities), and their reproduction in reports (such as the 2020 Aduriz-Lorenzo article in Lupus) aimed at rheumatologists, need to be mindful of the weaknesses of these methods. HCQ is such an essential therapy for our SLE patients that stopping it due to incorrect diagnoses of HCQ retinopathy should be avoided as much as possible. We have seen this in our own practice where patients have been told they have HCQ retinopathy (based on VF 10-2 or SD-OCT testing), yet have an AMR expert identify an unrelated eye problem (using mfERG testing) as the cause for the test abnormalities. These patients have continued their HCQ with close follow-up by the retinologist, using mfERG technology. There is a differential diagnosis for SD-OCT and VF 10-2 changes that can look like HCQ damage It is essential to keep in mind the differential diagnosis for AMR based on these screening tests. Common causes of false-positive tests on SD-OCT and visual field testing include vitreomacular traction, retinal detachment, and age-related macular degeneration in our patients. Some less common causes of abnormalities on these tests include retinitis pigmentosa, infectious retinitis (syphilis, rubella), autoimmune (paraneoplastic) retinopathy, inherited retinal dystrophies (Stargardt disease, Bardet Biedl syndrome, enhanced S-cone syndrome, isolated bulls-eye maculopathy), pigmented paravenous chorioretinal atrophy, and traumatic retinopathy. Visual field testing can have false positives due to dry eye, glaucoma ,and cataracts.  Bull's eye retinopathy should be a thing of the past, if we use mfERG, SD-OCT, VF 10-2, and VF 24-2 (in Asians) properly Photo credit: "The Lupus Encyclopedia" edition 1 The superiority of mfERG for accurately diagnosing HCQ-retinopathy The Browning article states that the specificities of VF 10-2 is 92.5%, SD-OCT is 98.1%, while mfERG is 86.9%. These findings are misleading. First, in the Browning research study, HCQ was stopped in patients based upon a clinical judgment for AMR diagnosis. Second, VF 10-2 testing included both red target and white target testing. Red target testing is not as reliable as white target VF 10-2 testing. Also, a 20% error rate was allowed for VF testing, which is too high to be reliable. Third, the mfERG criteria used is not the current standard. Therefore, VF 10-2 and SD-OCT should not be used individually for diagnosis. However, they have excellent sensitivities for screening tests. The most recent research shows that mfERG testing has better sensitivity and specificity for AMR than either VF 10-2 or SD-OCT testing. Using mfERG and SD-OCT has 100% sensitivity for identifying ARM, while the currently accepted use of VF 10-2 and SD-OCT has only an 86% sensitivity. A British study recently showed a 95% specificity and sensitivity for mfERG in the diagnosis as a singular test (far superior to VF 10-2 and SD-OCT). Also, mfERG testing is useful for monitoring patients who have other retina problems. The highest standard of care for this issue is to use SD-OCT and VF 10-2 (white target) testing as screening tests (per the 2016 AAO recommendations). If abnormalities are present that can be seen in AMR, a referral should be given for mfERG testing by a retinologist experienced in AMR. We realize that mfERG testing is not available in all locations, so many patients will not have this luxury. In these cases, referral to a retinologist who does not have mfEFG technology would be the next best step before assuming a diagnosis of AMR. In the future, hopefully, mfERG will be more commonly available to allow even earlier identification of ARM (used as a screening test with SD-OCT) as well as allowing a more accurate diagnosis. AuthorDon Thomas, MD, author of "The Lupus Encyclopedia" and "The Lupus Secrets" New guidelines from the American College of Rheumatology for the COVID-19 vaccine COVID-19 vaccine: Please get yours! Revised 6/13/21 with new drugs to stop for vaccines per revised ACR recommendations February 2021, the American College of Rheumatology released recommendations on what to do with immunosuppressant drugs around the time of your COVID-19 vaccine. The reason for these recommendations is that some of our medicines can blunt the effects of the vaccine. Timing the drug to the vaccine to your medication can make a big difference. ALSO: They make other important recommendations as listed below. Make sure to share this with your family, friends, and other patients NOTE: - Do not do any of these without asking your rheumatologist first (let them know that you did read these up to date recommendations here) - PRINT these out for future reference for other vaccines - I also recommend these to my patients who get any vaccine, IF they are in remission or at low risk of flaring when they get the vaccine (again, do not do this without talking to your rheumatologist first) - I agree with all of these, except, I differ with the methotrexate recommendation, as per below The link to the full recommendations is below at the bottom of the post.  Drug recommendations summary:Abatacept IV (Orencia): Time vaccine administration so that the 1st vaccine occurs 4weeks after Orencia IV (i.e., the entire dosing interval), and postpone the subsequent IV Orencia by 1 week (i.e., a 5-week gap in total); no medication adjustment for the second vaccine dose Abatacept SQ (Orencia self injectable): Hold SQ abatacept both one week prior to and one week after the first COVID-19 vaccine dose (only); no interruption around the second vaccine dose Azathioprine (Imuran): No modification needed Belimumab (Benlysta): No modification needed Cyclophosphamide: No modification needed for pills. For the IV form, time CYC administration so that it will occur approximately 1 week after each vaccine dose, when feasible. Hydroxychloroquine (Plaquenil): No modification needed IVIG: No modification needed JAK inhibitors (Xeljanz, Olumiant, Rinvoq): Hold JAKi for 1 week after each vaccine dose Kineret: No modification needed Leflunomide (Arava): No modification needed Methotrexate: Hold MTX 1 week after each vaccine dose, for those with well-controlled disease NOTE Dr. Thomas' recommendations to his patients: "Hold MTX dose for 2 doses after each vaccine if you are doing well and in remission" (do not do without talking to your own doctor). This is based on the latest study results with the flu shot and methotrexate. Mycophenolate (CellCept, Myfortic): No modification needed Prednisone: No modification needed Rituximab (Rituxan): Assuming that patient's COVID-19 risk is low or is able to be mitigated by preventive health measures (e.g., self-isolation), schedule vaccination so that the vaccine series is initiated approximately 4 weeks prior to next scheduled rituximab cycle; after vaccination, delay RTX 2-4 weeks after 2nd vaccine dose, if disease activity allows. Sulfasalazine: No modification needed Tacrolimus and cyclosporine A: No modification needed TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab): No modification needed Tocilizumab (Actemra): No modification needed Voclosporin (Lupkynis): No modification needed  Other important recommendations from the ACR:- There is no preference of getting one vaccine over another (Pfizer, Moderna, J&J, AstraZeneca): Get whatever is available for you - Lab testing is NOT required after vaccines to assess response to the vaccine - Ask all household members, friends and loved-ones to get vaccinated to protect you (the cocoon effect) - If you don't believe in the vaccine, get vaccinated at least to protect those you love (Dr. Thomas' addition) - Get vaccinated even if your disease is active REFERENCE: ACR, COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases. Developed by the ACR COVID-19 Vaccine Clinical Guidance Task Force. This draft summary was approved by the ACR Board of Directors on February 8, 2021.. A full manuscript is pending journal peer review. AuthorDon Thomas, author of "The Lupus Encyclopedia" and "The Lupus Secrets" How lupus causes hair loss |
Note that Dr. Thomas' posts are for informational purposes only, and are not meant to be specific medical advice for individuals. Always seek the advice of your healthcare provider with any questions regarding your own medical situation.
AuthorDONALD THOMAS, MD Archives
June 2021
Categories
All
|
RSS Feed
BUY ON AMAZON
|
The Lupus Encyclopedia: A Comprehensive Guide for Patients and Families (A Johns Hopkins Press Health Book) Illustrated Edition
|
TheLupusEncyclopedia©2020AllRights Reserved